GILEAD SCIENCES SL
- Country
- 🇪🇸Spain
- Ownership
- -
- Established
- 1994-01-01
- Employees
- -
- Market Cap
- $95.8B
Safety and Efficacy of the Combination of Tirabrutinib and Entospletinib With and Without Obinutuzumab in Adults With Chronic Lymphocytic Leukemia (CLL)
- Conditions
- Interventions
- First Posted Date
- 2016-12-06
- Last Posted Date
- 2021-12-21
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 36
- Registration Number
- NCT02983617
- Locations
- 🇩🇪
Evangelisches Diakoniekrankenhaus Bremen Hämatologie, Bremen, Germany
🇩🇪Universitätsklinikum Heidelberg, Abteilung Innere Medizin V, Heidelberg, Germany
🇩🇪Uniklinik Köln Klinik I für Innere Medizin, Köln, Germany
Study to Evaluate Efficacy and Safety of Switching From TDF to TAF in Adults With Chronic Hepatitis B Who Are Virologically Suppressed
- Conditions
- Interventions
- First Posted Date
- 2016-12-01
- Last Posted Date
- 2020-09-14
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 490
- Registration Number
- NCT02979613
Study to Evaluate the Safety and Efficacy of the Combination of Tirabrutinib and Idelalisib With and Without Obinutuzumab in Adults With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
- Conditions
- Interventions
- First Posted Date
- 2016-11-18
- Last Posted Date
- 2022-01-21
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 35
- Registration Number
- NCT02968563
- Locations
- 🇩🇪
Ambulante Krebszentrum Schaubstraße, Frankfurt, Brandenburg, Germany
🇩🇪KH Maria Hilf-Franziskushaus, Mönchengladbach, Mönchengladbach, Germany
🇩🇪Klinikum Rechts der Isar der Technischen Universität München, München, Germany
Pharmacokinetics of Lanraplenib in Adults With Impaired Renal Function
- First Posted Date
- 2016-11-08
- Last Posted Date
- 2019-10-25
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 36
- Registration Number
- NCT02959138
- Locations
- 🇳🇿
Christchurch Clinical Studies Trust, Christchurch, New Zealand
🇳🇿Auckland Clinical Studies, Grafton, Auckland, New Zealand
🇺🇸Clinical Pharmacology of Miami, Inc. (CPMI), Miami, Florida, United States
Study of Magrolimab (Hu5F9-G4) in Combination With Cetuximab in Participants With Solid Tumors and Advanced Colorectal Cancer
- First Posted Date
- 2016-11-03
- Last Posted Date
- 2021-03-01
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 78
- Registration Number
- NCT02953782
- Locations
- 🇺🇸
Md Anderson, Houston, Texas, United States
🇺🇸START Midwest, Grand Rapids, Michigan, United States
🇺🇸Wayne State University, Detroit, Michigan, United States
Trial of Magrolimab (Hu5F9-G4) in Combination With Rituximab or Rituximab + Chemotherapy in Participants With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2016-11-02
- Last Posted Date
- 2024-05-23
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 178
- Registration Number
- NCT02953509
- Locations
- 🇺🇸
Georgia Cancer Center at Augusta University, Augusta, Georgia, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸University of Minnesota Medical Center, Fairview, Minneapolis, Minnesota, United States
Harvoni in Patients With Chronic Hepatitis C Virus (HCV) Infection in Korea
- First Posted Date
- 2016-11-01
- Last Posted Date
- 2021-11-29
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 1081
- Registration Number
- NCT02951364
- Locations
- 🇰🇷
Busan St. Mary's Hospital, Busan, Korea, Republic of
🇰🇷Kosin University Gospel Hospital, Busan, Korea, Republic of
🇰🇷WonKwang University Hospital, Iksan, Korea, Republic of
Study to Evaluate the Safety, Tolerability, and Efficacy of Cilofexor in Adults With Primary Biliary Cholangitis Without Cirrhosis
- Conditions
- Interventions
- First Posted Date
- 2016-10-24
- Last Posted Date
- 2020-09-22
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 71
- Registration Number
- NCT02943447
Study to Evaluate the Safety, Tolerability, and Efficacy of Cilofexor in Adults With Primary Sclerosing Cholangitis Without Cirrhosis
- Conditions
- Interventions
- First Posted Date
- 2016-10-24
- Last Posted Date
- 2021-06-07
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 52
- Registration Number
- NCT02943460
- Locations
- 🇺🇸
The Liver Institute at Methodist Dallas Medical Center, Dallas, Texas, United States
🇦🇹Universitätsklinik Klinik für Innere Medizin III, Vienna, Austria
🇨🇦University of Calgary Liver Unit (Heritage Medical Research Clinic), Calgary, Alberta, Canada
Study of Tenofovir Alafenamide (TAF) in Children and Teen Participants With Chronic Hepatitis B Virus Infection
- First Posted Date
- 2016-10-13
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 150
- Registration Number
- NCT02932150
- Locations
- 🇺🇸
Seattle Children's Hospital, Seattle, Washington, United States
🇺🇸University of Miami/Schiff Center for Liver Diseases, Miami, Florida, United States
🇨🇦The Hospital for Sick Children, Toronto, Canada